Menu

Cell and Gene Therapy Tracker: Global CAR T-Cell Trials

Investigators have launched numerous clinical trials that test the efficacy of the immunotherapy. Here is a global accounting of these experiments.

Aug 22, 2018
The Scientist Staff

With our partners at CellTrials.org, we've developed an interactive map that displays the numbers of CAR T-cell trials taking place in countries across the world. Trials are categorized as targeting either hematologic malignancies or solid tumors. Click a country on the map to access the data on trials occurring there or scroll through the list of countries using the arrows to the left or right of the country name.

Infographic created with data compiled by CellTrials.org.

Researchers developed the first chimeric antigen receptor T cells, modified immune cells that can recognize tough-to-target cancer antigens, about three decades ago. In the past 20 years, scientists have tweaked CAR-T cells to become potent weapons against tumors. These efforts have been rewarded with several recent approvals by the US Food and Drug Administration (FDA). Last year, the FDA approved the first CAR T-cell therapy, Kymriah, which was developed by pharmaceutical giant Novartis and uses modified patient immune cells to target a particularly recalcitrant type of acute lymphoblastic leukemia. Later in 2017, the FDA granted approval to California-based Kite Pharma, which developed Yescarta, a similar CAR T-cell therapy for patients whose large B-cell lymphoma fails to respond to two other types of cancer treatments.

A number of other companies are conducting their own trials to attain regulatory approval for their own approaches to CAR T-cell therapy, which shares attributes of cell therapy, gene therapy, and immunotherapy.

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.